Nathan Jorgensen
2022
In 2022, Nathan Jorgensen earned a total compensation of $2.2M as Chief Financial Officer at Vor Biopharma, a 302% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $170,126 |
|---|---|
| Option Awards | $1,102,050 |
| Salary | $418,000 |
| Stock Awards | $456,660 |
| Other | $20,353 |
| Total | $2,167,189 |
Jorgensen received $1.1M in option awards, accounting for 51% of the total pay in 2022.
Jorgensen also received $170.1K in non-equity incentive plan, $418K in salary, $456.7K in stock awards and $20.4K in other compensation.
Rankings
In 2022, Nathan Jorgensen's compensation ranked 1,639th out of 5,625 executives tracked by ExecPay. In other words, Jorgensen earned more than 70.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,639 out of 5,625 | 71st |
Division Manufacturing | 845 out of 3,053 | 72nd |
Major group Chemicals And Allied Products | 332 out of 1,380 | 76th |
Industry group Drugs | 306 out of 1,281 | 76th |
Industry Biological Products, Except Diagnostic Substances | 77 out of 295 | 74th |
Source: SEC filing on April 14, 2023.
Jorgensen's colleagues
We found two more compensation records of executives who worked with Nathan Jorgensen at Vor Biopharma in 2022.